- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03909893
A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer (ARTGU)
March 15, 2024 updated by: University Health Network, Toronto
Radical radiation therapy for prostate cancer is a common treatment that has shown to improve clinical outcomes in a post-operative setting.
However, radiation therapy after surgery poses a greater risk for bladder and rectum injury for patients with prostate or bladder cancer.
For prostate cancer patients, the risk is further amplified when pelvic nodes are part of the target irradiated volume.
For bladder cancer patients, the risk of injury increases when more of the bladder is part of the target volume.
Using an adaptive radiation therapy approach allows for correcting any shifts in the target volume.
ART approach uses images from treatment to adapt the treatment plan.
This study will use Adaptive Radiation Therapy for patients who receive pelvic nodal radiotherapy for either prostate or bladder cancer.
Their treatment plans will adapted using MRI scans and CBCT scans taken during their first week of radiotherapy to account for any shifts in the target volume.
The purpose of this study is to evaluate the feasibility of ART approach and its and on treatment plan quality metrics for pelvic radiotherapy.
Acute and late toxicities will also be evaluated.
40 participants (minimum of 10 bladder cancer patients) will be enrolled.
The participants will be followed for a period of 5 years post radiation therapy, during which they will have PSA as per standard practice, along with follow-up questionnaires (EPIC for prostate cancer patients and BUSS for bladder cancer patients).
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Peter Chung, MD
- Phone Number: 6522 416-946-4501
- Email: peter.chung@rmp.uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network, Princess Margaret Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Histologic diagnosis of adenocarcinoma of the prostate after radical prostatectomy:
- Clinical stage pT3, pT4, or pT2 with positive margin; OR,
- any p-stage with persistently elevated post-operative PSA > 0.05ng/mL; OR,
- a delayed rise in PSA post-operative
Histologic diagnosis of transitional cell carcinoma of the bladder with intact bladder and:
- Clinical stage cT2, cT3, cT4, and N0 or N1
Exclusion Criteria:
- Inflammatory bowel disease or other contraindications to radiotherapy.
- Prior pelvic radiotherapy
- Previous cytotoxic chemotherapy
- Evidence of systemic metastases on imaging
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adaptive Radiation Therapy
|
Cone-beam CT images as well as MRI scans will be used to make any changes to the radiation treatment plan, part of the way through the treatment.
Adaptation of treatment plans may allow smaller target volumes to be treated with higher doses, while minimizing the side effects to surrounding organs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dosimetry
Time Frame: 5 years
|
Difference in dose-volume irradiation of critical organs between original and adapted plan will be compared.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity in Patients
Time Frame: Before Radiation Therapy, and at Month 3, Year 1, 3 & 5 after Radiation Therapy
|
To determine a preliminary measure of toxicity with this technique.
CTCAE toxicity data will be described for this population.
|
Before Radiation Therapy, and at Month 3, Year 1, 3 & 5 after Radiation Therapy
|
Bladder Cancer Patients' Quality of Life Function
Time Frame: Before Radiation Therapy, and at Month 3, Year 1, 3 & 5 after Radiation Therapy
|
Bladder Utility Symptom Scale (BUSS) questionnaires will be scored and analyzed to determine QoL function.
BUSS will be scored (1-100) as per standard criteria.
Data will be analyzed as a continuous variable
|
Before Radiation Therapy, and at Month 3, Year 1, 3 & 5 after Radiation Therapy
|
Prostate Cancer Patients' Quality of Life Function
Time Frame: Before Radiation Therapy, and at Month 3, Year 1, 3 & 5 after Radiation Therapy
|
Expanded Prostate Cancer Index Composite (EPIC) questionnaires will be scored and analyzed to determine QoL function.
EPIC will be scored (1-100) as per standard criteria.
Data will be analyzed as a continuous variable
|
Before Radiation Therapy, and at Month 3, Year 1, 3 & 5 after Radiation Therapy
|
Biochemical Control in Prostate Patients
Time Frame: PSA will be done before Radiation Therapy, and at Month 3, Year 1, 3 and 5 after Radiation Therapy
|
For prostate patients, patients will be considered to have biochemical failure if the PSA has risen 2ng above nadir.
|
PSA will be done before Radiation Therapy, and at Month 3, Year 1, 3 and 5 after Radiation Therapy
|
Local Control in Bladder Patients
Time Frame: 5 years
|
Local control will be defined by an absence of clinically locally recurrent disease
|
5 years
|
Feasibility of the use of Fiducial markers for bladder RT: quality of target delineation using fiducial markers
Time Frame: 5 years
|
Feasibility will be determined by analyzing the quality of target delineation using fiducial markers in bladder cancer patients.
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Peter Chung, MD, Princess Margaret Cancer Centre - University Health Network
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2023
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
January 1, 2025
Study Registration Dates
First Submitted
May 14, 2018
First Submitted That Met QC Criteria
April 8, 2019
First Posted (Actual)
April 10, 2019
Study Record Updates
Last Update Posted (Actual)
March 19, 2024
Last Update Submitted That Met QC Criteria
March 15, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-5929
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Adaptive Radiation Therapy
-
University Hospital, EssenRecruitingCervical Carcinoma | Radiation | Adaptive Radiotherapy | Image Guided Radiotherapy | Gynecological Tumor | Optimization | Curative Treatment | Adaptive Radiation TherapyGermany
-
University of Michigan Rogel Cancer CenterNational Institutes of Health (NIH)CompletedHepatocellular CarcinomaUnited States
-
Institut Paoli-CalmettesUnknown
-
Herlev HospitalRecruitingAnal Squamous Cell Carcinoma | Anal Cancer | Anal CarcinomaDenmark
-
Charite University, Berlin, GermanyRecruitingHead and Neck Cancer | Esophageal Cancer | NSCLC | Prostate Cancer | SCLC | Bladder Cancer | Cervix Cancer | Rectum Cancer | Other CarcinomaGermany
-
Varian, a Siemens Healthineers CompanyRecruitingCervical Cancer by FIGO Stage 2018United States
-
Massachusetts General HospitalVarian Medical SystemsRecruitingLymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell LymphomaUnited States
-
Peking Union Medical College HospitalNot yet recruitingRectal Cancer
-
Varian, a Siemens Healthineers CompanyRigshospitalet, Denmark; Herlev HospitalRecruitingMuscle-Invasive Bladder CarcinomaDenmark
-
University of RochesterVarian Medical SystemsRecruitingRecurrent Prostate Cancer After SurgeryUnited States